现代报告在MRNA流感、RSV和癌症疫苗方面取得成功,将其推向更大的试验阶段。 Moderna reports success in mRNA flu, RSV, and cancer vaccines, advancing them to larger trials.

Moderna 正在将其 mRNA 技术扩展到 COVID-19 疫苗之外，报告了流感和 RSV 候选药物的 2 期阳性结果，这些候选药物具有强大的免疫反应和对高危人群的保护。 Moderna is expanding its mRNA technology beyond COVID-19 vaccines, reporting positive Phase 2 results for flu and RSV candidates with strong immune responses and protection in high-risk groups. 该公司正在将流感和抗逆转录病毒疫苗推广到规模更大的第三阶段试验,并测试乳腺瘤和肺癌的个人化癌症疫苗,早期迹象显示结果有所改善。 The company is advancing flu and RSV vaccines into larger Phase 3 trials and testing personalized cancer vaccines in melanoma and lung cancer, showing early signs of improved outcomes. 这些发展突显了现代大学在一系列传染病和个性化癌症治疗方面推动使用MRNA。 These developments highlight Moderna’s push to use mRNA for a range of infectious diseases and individualized cancer treatments.